These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25312286)

  • 21. [New therapeutic strategy for autoimmune diseases. 3) Treatment of autoimmune diseases by cytokine signal transduction inhibition].
    Nishimoto N; Yoshizaki K; Kishimoto T
    Nihon Naika Gakkai Zasshi; 1998 Sep; 87(9):1745-50. PubMed ID: 9816842
    [No Abstract]   [Full Text] [Related]  

  • 22. Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer.
    Ataie-Kachoie P; Pourgholami MH; Morris DL
    Cytokine Growth Factor Rev; 2013 Apr; 24(2):163-73. PubMed ID: 23107589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Interferons and autoimmune diseases].
    Niino M; Miyazaki Y
    Brain Nerve; 2013 Nov; 65(11):1381-8. PubMed ID: 24200616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin-6: from an inflammatory marker to a target for inflammatory diseases.
    Rincon M
    Trends Immunol; 2012 Nov; 33(11):571-7. PubMed ID: 22883707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Contribution of Japanese researchers to progress in the study of allergy and collagen disease in the last 100 years: IL-6 and autoimmune diseases].
    Nishimoto N
    Nihon Naika Gakkai Zasshi; 2002 Sep; 91(9):2604-7. PubMed ID: 12373879
    [No Abstract]   [Full Text] [Related]  

  • 26. Interleukin-6 and IL-6 receptor cell expression in testis of rats with autoimmune orchitis.
    Rival C; Theas MS; Guazzone VA; Lustig L
    J Reprod Immunol; 2006 Jun; 70(1-2):43-58. PubMed ID: 16458979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses.
    Hohki S; Ohguro N; Haruta H; Nakai K; Terabe F; Serada S; Fujimoto M; Nomura S; Kawahata H; Kishimoto T; Naka T
    Exp Eye Res; 2010 Aug; 91(2):162-70. PubMed ID: 20420831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting IL-23 in autoimmunity.
    Hölscher C
    Curr Opin Investig Drugs; 2005 May; 6(5):489-95. PubMed ID: 15912962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-6 and its receptors: a highly regulated and dynamic system.
    Wolf J; Rose-John S; Garbers C
    Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The IL-17 pathway as a major therapeutic target in autoimmune diseases.
    Hu Y; Shen F; Crellin NK; Ouyang W
    Ann N Y Acad Sci; 2011 Jan; 1217():60-76. PubMed ID: 21155836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic potential of STAT4 in autoimmunity.
    Liang Y; Pan HF; Ye DQ
    Expert Opin Ther Targets; 2014 Aug; 18(8):945-60. PubMed ID: 24844303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on the role of Interleukin 17 in rheumatologic autoimmune diseases.
    Konya C; Paz Z; Apostolidis SA; Tsokos GC
    Cytokine; 2015 Oct; 75(2):207-15. PubMed ID: 26028353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IL-6/IL-6 receptor system and its role in physiological and pathological conditions.
    Mihara M; Hashizume M; Yoshida H; Suzuki M; Shiina M
    Clin Sci (Lond); 2012 Feb; 122(4):143-59. PubMed ID: 22029668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunology. Targeting the tolls.
    Wickelgren I
    Science; 2006 Apr; 312(5771):184-7. PubMed ID: 16614188
    [No Abstract]   [Full Text] [Related]  

  • 35. Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interluekin-6 receptor antibody.
    Mihara M; Ohsugi Y; Kishimoto T
    Biofactors; 2009; 35(1):47-51. PubMed ID: 19319845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting IL-17 in autoimmunity and inflammation.
    Kim BS; Park YJ; Chung Y
    Arch Pharm Res; 2016 Nov; 39(11):1537-1547. PubMed ID: 27576555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CTLA4-Ig suppresses development of experimental autoimmune uveitis in the induction and effector phases: Comparison with blockade of interleukin-6.
    Iwahashi C; Fujimoto M; Nomura S; Serada S; Nakai K; Ohguro N; Nishida K; Naka T
    Exp Eye Res; 2015 Nov; 140():53-64. PubMed ID: 26297802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition.
    Garbers C; Aparicio-Siegmund S; Rose-John S
    Curr Opin Immunol; 2015 Jun; 34():75-82. PubMed ID: 25749511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer.
    Taniguchi K; Karin M
    Semin Immunol; 2014 Feb; 26(1):54-74. PubMed ID: 24552665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer.
    Neurath MF; Finotto S
    Cytokine Growth Factor Rev; 2011 Apr; 22(2):83-9. PubMed ID: 21377916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.